Source:http://linkedlifedata.com/resource/pubmed/id/12581567
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2003-2-12
|
| pubmed:abstractText |
Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 disease, however, proves to be difficult with current diagnostic tests. Distant metastases may become clinically overt during induction chemotherapy (IC) or shortly after, revealing the inaccuracies of current staging algorithms. A prospective study with [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in IIIA-N2 NSCLC patients was performed to assess its value in the selection of this patient group. Fifty-seven patients received a whole body FDG PET scan as part of an ongoing response monitoring trial. Results were compared with conventional staging. In 32/57 (56%) PET suggested upstaging, which was confirmed in 17/57 (30%) with a median follow-up of 16 (range 2-49) months. These results show that using the conventional staging algorithm a substantial group of patients was understaged. FDG PET improves the selection of patients suitable for CMT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0169-5002
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2002 Elsevier Science Ireland Ltd.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
151-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12581567-Adenocarcinoma,
pubmed-meshheading:12581567-Adult,
pubmed-meshheading:12581567-Aged,
pubmed-meshheading:12581567-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12581567-Carcinoma, Squamous Cell,
pubmed-meshheading:12581567-Combined Modality Therapy,
pubmed-meshheading:12581567-Female,
pubmed-meshheading:12581567-Fluorine Radioisotopes,
pubmed-meshheading:12581567-Fluorodeoxyglucose F18,
pubmed-meshheading:12581567-Follow-Up Studies,
pubmed-meshheading:12581567-Humans,
pubmed-meshheading:12581567-Lung Neoplasms,
pubmed-meshheading:12581567-Male,
pubmed-meshheading:12581567-Middle Aged,
pubmed-meshheading:12581567-Neoplasm Staging,
pubmed-meshheading:12581567-Patient Selection,
pubmed-meshheading:12581567-Prospective Studies,
pubmed-meshheading:12581567-Radiopharmaceuticals,
pubmed-meshheading:12581567-Tomography, Emission-Computed
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
|
| pubmed:affiliation |
Clinical PET Centre, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
|
| pubmed:publicationType |
Journal Article
|